State of the Art of CNS Drug Discovery and Development
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Chemical and Molecular Sciences".
Deadline for manuscript submissions: closed (20 September 2022) | Viewed by 3828
Special Issue Editor
Interests: chemistry of cosmetics; organic chemistry; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It has nearly been a hundred years since new synthetic compounds were first tried on humans—starting with accidental observations of activity, through methodological search for active compounds. Then, norms and programs for activity and safety measurements were elaborated and many efforts were made to fight diseases and drug abuse arising from the consumption of CNS drugs. As a result, many compounds were delegalized.
Some problems regarding CNS diseases have been solved, and many have been dealt with partially. Many have been a starting point for more research and better understanding of receptor structures, biochemical processes, and development of diseases. A lot of research interest has been focused on chiral drugs and isomerization, liberation, absorption, distribution, metabolism, elimination (LADME) processes, and new IT technologies for the determination of potential binding to receptors or possible toxicity.
The recent pandemic has shifted the research interest of pharma companies to other areas of interest for drug candidates; therefore, this is a great opportunity to sum up recent achievements in CNS drug discovery.
Dr. Anna Waszkielewicz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CNS drug discovery
- drug candidates
- synthesis
- LADME
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
